Saturday 17 October 2026
Export PRCT’s income statement to Excel — free account
PROCEPT BioRobotics Corporation
PRCT Healthcare Medical Devices
PROCEPT BioRobotics Corporation’s revenue for fiscal 2025 (year ended December 2025) was $308.1 million, up 37.2% from fiscal 2024. In the quarter to June 2026, revenue grew 19.3%, EPS fell 34.3%, free cash flow fell 24.4% and total debt was flat, each against the same quarter a year earlier. Revenue growth for five consecutive years; insiders bought in the last twelve months.
17.57
0.58
−3.20%
Follow PRCT
| Dec '17 | Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | Dec '24 | Dec '25 | |
|---|---|---|---|---|---|---|---|---|
Piotroski F-Score |
— | — | — | 6 | 4 | 3 | 5 | 5 |
P/E ratio |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Altman Z-Score |
— | — | — | 3.13 | 8.58 | 8.36 | 18.46 | 6.44 |
P/S ratio |
— | 0.00 | 0.00 | 11.96 | 23.42 | 14.38 | 18.70 | 5.67 |
P/FCF ratio |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Altman Z″-Score (non-manufacturers) |
— | (11.71) | (1.80) | 6.43 | 1.45 | 1.84 | 3.92 | 2.18 |
Beneish M-Score |
— | — | — | (0.49) | 0.65 | (0.98) | (1.90) | (2.86) |
P/Operating CF |
— | (18.18) | (18.18) | (25.02) | (69.77) | (78.98) | (129.58) | (169.21) |
P/B ratio |
— | 0.00 | 0.00 | 1.54 | 8.91 | 6.98 | 10.43 | 4.78 |
Price to Tangible BV |
— | 0.00 | 0.00 | 1.55 | 8.98 | 7.01 | 10.46 | 4.79 |
EV/Sales |
— | 0.00 | 0.00 | 4.68 | 21.18 | 12.88 | 17.45 | 4.92 |
EV/EBITDA |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
EV/Operating CF |
— | (1.70) | (1.70) | (2.82) | (19.77) | (16.24) | (39.48) | (30.92) |
EV/FCF |
— | (1.69) | (1.69) | (2.79) | (19.14) | (13.17) | (37.80) | (25.96) |
Quick Ratio |
— | 6.35 | 7.00 | 19.01 | 6.74 | 6.65 | 7.85 | 5.62 |
Current Ratio |
— | 7.42 | 7.59 | 20.08 | 7.73 | 7.63 | 9.07 | 6.85 |
Net Debt/EBITDA |
— | 0.45 | 1.06 | 4.93 | 2.15 | 1.94 | 3.07 | 2.41 |
Debt/Assets |
0.00% | 37.46% | 41.63% | 15.91% | 17.82% | 13.15% | 10.01% | 10.16% |
Debt/Equity |
— | 0.79 | 0.86 | 0.20 | 0.28 | 0.19 | 0.13 | 0.14 |
Asset Turnover |
— | 0.20 | 0.08 | 0.15 | 0.23 | 0.38 | 0.48 | 0.59 |
Operating CF/Net income |
— | 1.04 | 0.91 | 0.96 | 0.92 | 1.02 | 1.09 | 0.51 |
Capex/Depreciation |
— | 0.00 | (0.08) | (0.18) | (0.93) | (6.62) | (0.84) | (1.46) |
Interest Coverage |
— | (46.50) | (9.09) | (9.32) | (15.57) | (27.33) | (23.09) | (28.96) |
| — | 25.69% | 32.45% | (142.17%) | (37.55%) | (44.32%) | (26.77%) | (24.89%) | |
| — | (135.41%) | (56.41%) | (25.85%) | (26.97%) | (29.66%) | (19.48%) | (18.34%) | |
ROIC |
— | 0.00% | (225.01%) | (206.72%) | (170.70%) | (88.89%) | (49.51%) | (49.56%) |
Return on Tangible Assets |
— | (80.97%) | (50.98%) | (19.00%) | (35.43%) | (31.76%) | (20.07%) | (23.03%) |
Average Days of Receivables |
— | 65.02 | 73.26 | 47.26 | 74.31 | 129.65 | 135.75 | 98.97 |
Research and Development Expense of Revenue |
— | 213.11% | 210.90% | 55.10% | 38.63% | 35.57% | 27.75% | 23.14% |
Selling, General and Administrative Expense of Revenue |
— | 462.28% | 392.28% | 148.05% | 118.42% | 96.76% | 76.35% | 74.28% |
Intangible Assets out of Total Assets |
0.00 | 0.04 | 0.02 | 0.01 | 0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
— | 0.00% | 28.16% | 11.01% | 13.78% | 14.05% | 14.18% | 15.45% |
Graham Net Nets |
— | 0.75 | 0.75 | 0.62 | 0.09 | 0.12 | 0.08 | 0.18 |
Graham Number |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Earnings Yield |
— | (24.26%) | (24.26%) | (27.59%) | (4.95%) | (5.41%) | (2.19%) | (5.44%) |
Free Cash Flow Yield |
— | (32.73%) | (32.73%) | (14.05%) | (4.73%) | (6.80%) | (2.47%) | (3.34%) |
Revenue per Share |
— | 0.14 | 2.11 | 2.09 | 1.69 | 2.88 | 4.31 | 5.55 |
Operating CF per Share |
— | (1.01) | (13.20) | (3.48) | (1.81) | (2.29) | (1.90) | (0.88) |
Capex per Share |
— | 0.00 | (0.06) | (0.04) | (0.06) | (0.53) | (0.08) | (0.17) |
Free Cash Flow per Share |
— | (1.01) | (13.26) | (3.51) | (1.87) | (2.82) | (1.99) | (1.05) |
Cash per Share |
— | 0.97 | 27.34 | 18.47 | 5.01 | 5.44 | 6.40 | 5.16 |
Shareholders Equity per Share |
— | 0.68 | 16.64 | 16.21 | 4.44 | 5.94 | 7.72 | 6.59 |
Interest Debt per Share |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
— | 0.68 | 16.64 | 16.21 | 4.44 | 5.94 | 7.72 | 6.59 |
Free Cash Flow |
— | (43.82) | (48.58) | (57.93) | (83.03) | (133.21) | (103.62) | (58.34) |
Working Capital |
— | 43.57 | 95.73 | 309.93 | 237.34 | 304.64 | 428.71 | 384.58 |
Capital Expenditures |
— | (7.61) | (0.23) | (0.59) | (2.65) | (25.21) | (4.41) | (9.36) |
Net Current Asset Value |
— | 17.59 | 45.25 | 256.24 | 160.37 | 226.60 | 350.05 | 308.17 |
EV/EBIT |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Capex to Sales |
— | 0.00 | 0.03 | 0.02 | 0.04 | 0.19 | 0.02 | 0.03 |
Price to Operating Income |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other line items | ||||||||
Depreciation/Fixed assets |
— | 0.18 | 0.35 | 0.66 | 0.33 | 0.13 | 0.20 | 0.21 |
Cash ROIC |
— | (46.38%) | (22.75%) | (9.27%) | (17.49%) | (22.53%) | (13.13%) | (8.29%) |
Accounts Receivable Turnover |
— | 4.66 | 5.83 | 11.47 | 7.60 | 4.28 | 3.40 | 3.69 |
Accounts Payable Turnover |
— | 6.00 | 6.69 | 11.38 | 6.64 | 5.69 | 7.43 | 8.19 |
Inventory Turnover |
— | 1.14 | 1.32 | 1.85 | 1.82 | 1.91 | 1.82 | 1.76 |
Average Days of Payables |
— | 65.44 | 50.45 | 39.80 | 90.37 | 75.64 | 41.90 | 56.42 |
Days of Inventory on Hand |
— | 303.00 | 281.68 | 257.88 | 274.68 | 222.76 | 234.57 | 230.74 |
Average Receivables |
— | 1.32 | 1.32 | 3.01 | 9.87 | 31.82 | 65.94 | 83.51 |
Average Payables |
— | 1.34 | 1.34 | 1.63 | 5.71 | 11.45 | 11.77 | 13.66 |
Average Inventory |
— | 7.08 | 6.81 | 10.04 | 20.85 | 34.15 | 47.96 | 63.43 |
Average Assets |
— | 31.00 | 93.98 | 231.50 | 323.18 | 357.02 | 469.37 | 521.05 |
Average Common Equity |
— | (163.37) | (163.37) | 42.10 | 232.08 | 238.91 | 341.49 | 384.05 |
Columns are period end dates